Emergent BioSolutions Expands Its Baltimore, Maryland, Manufacturing Hub
02/04/2015
“Emergent BioSolutions’ expansion in Baltimore City is great news and underscores our commitment to biotechnology manufacturing and to our rich research and development environment,” said Baltimore Development Corporation President/CEO William H. Cole. “In 2009, BDC facilitated the sale of city-owned land to Emergent on which its facility sits; and in 2014, we assisted the company in acquiring additional property for its expansion. I am proud that BDC has played a pivotal role in Emergent’s continuing growth and in job creation for the city’s bioscience and manufacturing sectors.”
The State is supporting Emergent’s expansion through a previously approved $2 million conditional loan from DBED’s Maryland Economic Development Assistance Authority and Fund. The loan was offered to help start this two-phase project—phase one supported the relocation and expansion of the company’s headquarters and research and development site in Gaithersburg, as well as the anticipated addition of 133 new employees.
“Emergent has enjoyed considerable growth since first establishing its headquarters in Maryland over a decade ago,” said Daniel J. Abdun-Nabi, President/CEO of Emergent BioSolutions. “We are pleased to continue to expand our footprint and remain committed to making Maryland one of the most vibrant life sciences hubs in the country. We thank the state and local governments for fostering economic initiatives to support companies such as Emergent in its mission of protecting and enhancing life.”
“Emergent Biosolutions’ decision to continue to invest in our State means more jobs and more opportunities for Marylanders,” said Maryland Department of Business & Economic Development Secretary Mike Gill. “The company’s recent expansion of its headquarters in Gaithersburg combined with this expansion project is expected to create close to 300 new jobs and helps solidify Maryland’s position as a life sciences powerhouse.”
In a cost-sharing contract awarded to Emergent in 2012, the U.S. Department of Health and Human Services committed $222 million to establish Emergent’s Baltimore facility as a Center for Innovation in Advanced Development and Manufacturing to facilitate advanced development of medical countermeasures and provide domestic surge manufacturing capabilities to address public health threats. Recently, Emergent was one of the companies tapped by the Biomedical Advanced Research and Development Authority to investigate producing ZMapp, an experimental drug for Ebola. The company also manufactures BioThrax, Anthrax Vaccine Adsorbed, the only FDA-licensed vaccine for the prevention of anthrax disease.
Project Announcements
Bosch Expands Lincolnton, North Carolina, Operations
06/02/2023
Little Leaf Farms Establishes McAdoo, Pennsylvania, Greens Production Complex
06/02/2023
Swiss-Based Sulzer Pumps Solutions Plans Easley, South Carolina, Operations
06/01/2023
Finland-Based ADMARES Plans Waycross, Georgia, U.S. Manufacturing Plant
06/01/2023
Toyota Plans Georgetown, Kentucky, Electric Vehicle Operations
06/01/2023
Ranger Design Establishes North Charleston, South Carolina, Operations
05/31/2023
Most Read
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
Is a Flurry of Fads Shaping Economic Development Policy?
Q2 2023
-
Nearshoring — North America’s Next Factory
Q2 2023
-
Front Line: Water Supply Increasingly Affecting Location Decisions
Q2 2023
-
Life Science Conversions in Real Estate
Q2 2023
-
First Person: Labor Crunch in the Construction Industry
Q2 2023
-
Companies Are Recalibrating Their Priorities
Q1 2023